Gilead Sciences (GILD): HIV Empire Expanding as Prevention Boom and Cancer Pipeline Ignite Its Next Growth Wave!

$50.00 — or $120.00 / year

Gilead’s first-quarter results reinforce the view that the company has entered a more durable, innovation-driven growth phase anchored by HIV leadership, expanding prevention adoption, and a deepening oncology pipeline. Base business revenue grew 8% year over year to $6.8 billion, while non-GAAP EPS increased 12% to $2.03, supported by a structurally stronger margin profile with product gross margin expanding 200 basis points to 87% and operating margin reaching 47%. HIV remains the economic engine, with segment revenue rising 10% and Biktarvy maintaining over 52% U.S. market share, reinforcing long-duration earnings visibility through patent protection extending to 2036. Importantly, the prevention business is emerging as a major incremental growth vector, with U.S. PrEP revenue surging 87% and Yeztugo generating $166 million in quarterly sales, prompting management to raise its 2026 outlook to approximately $1 billion. Oncology is also becoming increasingly meaningful, as Trodelvy sales rose 37% amid expanding breast cancer indications, while the pending Anito-cel launch and broader Arcellx, Tubulis, and Ouro acquisitions significantly deepen Gilead’s future oncology platform. Despite policy-related pricing pressure, cell therapy competition, and integration risks tied to acquisitions, the company continues to demonstrate disciplined capital allocation, strong free cash flow generation, and sustained pipeline cadence across HIV and oncology. Can Gilead successfully convert its accelerating HIV prevention franchise and expanding oncology platform into a multi-engine growth model capable of offsetting future pricing pressure and sustaining long-term earnings reacceleration?

Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures

Related products

  • Steel Dynamics (STLD): Volume Takes Center Stage in Q2E ! Out of stock

    Steel Dynamics (STLD): Volume Takes Center Stage in Q2E !

     Read more
  • Nextracker Inc. (NXT): Increasing Competition May Impact Pricing & Margins,BUT Heres Why Growth is On-Track and Unwavering!

    Nextracker Inc. (NXT): Increasing Competition May Impact Pricing & Margins,BUT Heres Why Growth is On-Track and Unwavering!

     $50.00 — or $120.00 / year

    Nextracker has provided a positive outlook for fiscal year 2025, projecting continued growth in revenue and profitability. The company expects revenue in the range of $2.8 billion to $2.9 billion, representing approximately 14% year- over-year growth at the midpoint. Adjusted EBITDA is forecasted to be between $600 million and $650 million, implying a 20% growth year-over-year. The expected GAAP EPS ranges from $2.41 to $2.61 per share, while adjusted EPS is projected to be between $2.89 and $3.09 per share. Nextracker’s guidance reflects its confidence in its strategic initiatives and strong backlog, with over $4 billion in contracted bookings supporting the fiscal year 2025 outlook. In conclusion, Nextracker’s fiscal year 2024 performance underscores its robust market position and strategic execution. The company achieved significant growth in revenue, profitability, and backlog, driven by strong demand for its solar tracking solutions and strategic global expansion. Nextracker’s focus on innovation, quality, and reliability has enabled it to deliver superior financial returns for customers and establish itself as a leader in the renewable energy sector. While challenges such as market competition, regulatory changes, and supply chain complexities persist, Nextracker’s strong financial position and strategic initiatives position it well for continued growth. Given the positive outlook for fiscal year 2025, with projected increases in revenue and EBITDA, Nextracker is poised to capitalize on the expanding solar energy market.

    Select options This product has multiple variants. The options may be chosen on the product page
  • American Water: Strategic Rate Cases and Acquisitions - Key to a Secure Financial Future? 3 Pivotal Drivers- Out of stock

    American Water: Strategic Rate Cases and Acquisitions – Key to a Secure Financial Future? 3 Pivotal Drivers-

     Read more
Scroll to Top